alder biopharmaceuticals inc aldrfollow1260025 195nasdaq  health technology apr 6 2018 400 pm edtprev close 1285open 1270day lowhigh 1235  131552 wk lowhigh 860  2250volume 96375kavg volume 172mexchange nasdaqshares outstanding 6776mmarket cap 86056meps 500pe ratio nadiv  yield n a n asummary profile news financials events ownership options trade with jim cramer 14 days freelatest news alder biopharmaceuticals enters oversold territory aldralder bio pharmaceuticals® appoints paul b cleveland as interim president and chief executive officer alder bio pharmaceuticals® to present at 38th annual cowen  co health care conference mar 5 2018 405 pm estfirst week of october 19th options trading for alder biopharmaceuticals aldrinvestors in alder biopharmaceuticals inc saw new options begin trading this week for the october 19th expiration one of the key data points that goes into the price an option buyer is willing to pay is the time value so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration feb 27 2018 1137 am estalder bio pharmaceuticals reports fourth quarter and full year 2017 financial and operating results feb 26 2018 415 pm estalder bio pharmaceuticals® to host conference call to discuss fourth quarter and yearend 2017 financial and operating results feb 19 2018 800 am estalder bio pharmaceuticals inc announces exercise in full of underwriters option to purchase additional 250 convertible senior notes due 2025feb 13 2018 1047 am estalder bio pharmaceuticals® to present at two upcoming february investor conferences feb 8 2018 800 am estalder bio pharmaceuticals inc announces closing of 250 million of 250 convertible senior notes due 2025augments 100 million in gross proceeds received in the 250 million january 2018 committed equity financing with redmile group llc investors remaining 150 million undrawn capacity terminated feb 1 2018 1046 am estalder bio pharmaceuticals inc announces pricing of 250 million of 250 convertible senior notes due 2025jan 29 2018 1025 pm estalder bio pharmaceuticals inc announces offering of 200 million of convertible senior notes due 2025jan 29 2018 710 am estfirst week of aldr march 16th options trading investors in alder biopharmaceuticals inc saw new options become available this week for the march 16th expiration at stock options channel our yield boost formula has looked up and down the aldr options chain for the new march 16th contracts and identified one put and one call contract of particular interest jan 25 2018 1220 pm estfive rules for this market beast cramers mad money recap tues 11618even with mondays sharp reversal jim cramer says he still likes this market jan 17 2018 610 am esthow high can this market go  cramers mad money recap friday 11218jim cramer marvels at the market leadership from financials airlines and even tech stocks check out his game plan for next week jan 13 2018 702 am estalder bio pharmaceuticals cramers top takeaways randall schatzman cofounder president and ceo of alder bio pharmaceuticals tells jim cramer about migraine treatment eptinezumab jan 13 2018 651 am estalder announces 250 million committed equity financing jan 8 2018 800 am estalder bio pharmaceuticals® enters into european patent settlement and global license agreement with teva in the field of anticgrpbased therapy jan 8 2018 800 am estalder announces eptinezumab significantly reduces migraine risk meets primary and all key secondary endpoints in pivotal promise 2 phase 3 trial for chronic migraine prevention jan 8 2018 730 am estalder bio pharmaceuticals® to present at the 36th annual j p morgan healthcare conference jan 3 2018 700 am estfirst week of december 15th options trading for alder biopharmaceuticals aldrinvestors in alder biopharmaceuticals inc saw new options begin trading this week for the december 15th expiration at stock options channel our yield boost formula has looked up and down the aldr options chain for the new december 15th contracts and identified the following put contract of particular interest dec 4 2017 1040 am estaldr insiders vs shorts the most recent short interest data was recently released for the 10312017 settlement date and alder biopharmaceuticals inc is one of the most shorted stocks of the russell 3000 based on 731 days to cover versus the median component at 518 there are a number of ways to look at short data but one metric that we find particularly useful is the days to cover because it considers both the total shares short and the average daily volume of shares typically traded nov 27 2017 227 pm estalder bio pharmaceuticals® to present at 29th annual piper jaffray healthcare conference nov 22 2017 800 am estfirst week of aldr july 2018 options trading investors in alder biopharmaceuticals inc saw new options begin trading this week for the july 2018 expiration one of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration nov 21 2017 1118 am estcommit to purchase alder biopharmaceuticals at 750 earn 119 annualized using options investors eyeing a purchase of alder biopharmaceuticals inc stock but tentative about paying the going market price of 1193share might benefit from considering selling puts among the alternative strategies at their disposal one interesting put contract in particular is the april 2018 put at the 750 strike which has a bid at the time of this writing of 40 cents nov 8 2017 1144 am estalder bio pharmaceuticals® announces third quarter 2017 financial and operating results nov 7 2017 424 pm estalder bio pharmaceuticals® to present at 26th annual credit suisse healthcare conference nov 1 2017 800 am edtalder bio pharmaceuticals® to host conference call to discuss third quarter 2017 financial and operating results conference call set for 500 pm est november 7 2017oct 31 2017 800 am edtroku nucana and other ipos that should be on your radar in 2017newly public companies such as roku nu cana and restoration robotics could bring a jolt to your portfolio but remember all ipos arent created equally sep 27 2017 834 am edtmarket signals change of direction cramers mad money recap monday 91817jim cramer explains whats behind these markets moves both up and down he thinks changes are being caused by short sellers whose bets have gone awry sep 19 2017 629 am edtu s concrete alder biopharmaceuticals mad money lightning round jim cramer is bullish on u s concrete alder biopharmaceuticals dish network and berkshire hathaway sep 19 2017 628 am edtload more quant rating on 400 pm edt 462018d sellget the aldrreport here from our partners alder biopharmaceuticals pullback a buying opportunity says mizuho the fly biohaven seems attractive but a closer look puts it on the back burner seeking alpha positive latestage results for biohavens rimegepant fails to lift shares down 29 premarket seeking alpha midday gainers  losers 03212018seeking alpha healthcare  top 5 gainers  losers as of 1100 am 3212018seeking alpha alder bio steps down shares up 1 after hours seeking alpha your daily pharma scoop clovis q4 results endocyte update merrimack doses first patient in mm121 midstage study seeking alpha alder bio beats by 023seeking alpha notable earnings after monday’s close seeking alpha alder biopharmaceuticals makes a comeback seeking alpha biotech forum daily digest for january 31st seeking alpha your daily pharma scoop abeonas eb101 granted rmat designation teva to raise debt pfizer reports results seeking alpha alder biopharmaceuticals weakness a buying opportunity says canaccord the fly your daily pharma scoop sanofi to acquire ablynx ptc therapeutics announces data lutathera approved seeking alpha alder prices upsized convertible debt offering seeking alpha 